OncoMatch/Clinical Trials/NCT07102901
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Is NCT07102901 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SHR2554 Tablets and SHR-A1811 for advanced gastric cancer.
Treatment: SHR2554 Tablets · SHR-A1811 · SHR-A1904 · SHR-1701 — This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Disease stage
Metastatic disease required
Metastatic Gastric Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: enhancer of zeste homolog inhibitor
Has previously been treated with any enhancer of zeste homolog inhibitors.
Lab requirements
Cardiac function
No uncontrolled or significant cardiovascular disease
Uncontrolled or significant cardiovascular disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07102901 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior enhancer of zeste homolog inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages